


## PF-00956980

Cat. No.:	HY-108342
CAS No.:	1262832-74-5
Molecular Formula:	C <sub>18</sub> H <sub>26</sub> N <sub>6</sub> O
Molecular Weight:	342.44
Target:	JAK
Pathway:	Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	PF-00956980 is a reversible pan-JAK inhibitor with IC <sub>50</sub> values of 2.2, 23.1 and 59.9 μM for JAK1, JAK2 and JAK3, respectively. PF-00956980 can be used in the research of lung and skin inflammatory diseases <sup>[1]</sup> .						
<b>IC<sub>50</sub> &amp; Target</b>	JAK1 2.2 μM (IC <sub>50</sub> )	JAK2 23.1 μM (IC <sub>50</sub> )	JAK3 59.9 μM (IC <sub>50</sub> )				
<b>In Vivo</b>	The pharmacokinetic parameters of PF-00956980(compound 2) in rat or dog						
	Species	Dose (mg/kg)	Cl (mL/min/Kg)	Clunbound (mL/min/Kg)	V <sub>ss</sub> (L/Kg)	Terminal T <sub>1/2</sub> (h)	Oral Bioavailability
	Rat i.v.	0.5	48	>48,000	0.8	2.1	-
	Rat p.o.	1	-	-	-	-	<5%
	Dog i.v.	0.1	18	>18,000	1.0	2.0	-
	MCE has not independently confirmed the accuracy of these methods. They are for reference only.						

### REFERENCES

[1]. Peter Jones, et al. Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin. *J Med Chem.* 2017 Jan 26;60(2):767-786.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA